文献速递心力衰竭与心肌病

蛋白磷酸酶抑制剂-1基因治疗在非缺血性心力衰竭猪模型中的应用

Protein Phosphatase Inhibitor-1 Gene Therapy in a Swine Model of Nonischemic Heart Failure.
PubMed 文献 · J Am Coll Cardiol · 2017-01-01

研究在严重二尖瓣反流诱导的容量负荷性非缺血性心衰猪模型中,经冠状动脉递送BNP116.I-1c基因治疗。结果显示治疗组左室射血分数和左房射血分数改善,且未发现不良电重构、致心律失常性、细胞免疫激活或靶器官损伤。

要点

  • BNP116.I-1c基因治疗改善非缺血性心衰猪的左室收缩功能。
  • 治疗组左房射血分数显著增加,提示左房收缩功能改善。
  • 未观察到不良电重构、致心律失常性或靶器官损伤。

核心结论

  • 经冠状动脉递送BNP116.I-1c在非缺血性心衰大动物模型中安全,并改善左室和左房收缩性。

研究设计与样本

  • 约克夏猪经诱导严重二尖瓣反流建立容量负荷性心衰,1个月后随机接受冠状动脉内BNP116.I-1c(n=6)或生理盐水(n=7)。
  • 另用24只健康猪接受不同剂量BNP116.I-1c进行安全性评估。
  • 基因递送后2个月评估疗效与安全性。

主要发现

  • 治疗组左室射血分数变化为-5.9 ± 4.2% vs. 5.5 ± 4.0%(p < 0.001),校正dP/dt最大值变化为-3.39 ± 2.44 s-1 vs. 1.30 ± 2.39 s-1(p = 0.007)。
  • 治疗组左房射血分数变化为-4.3 ± 3.1% vs. 7.5 ± 3.1%(p = 0.02)。
  • 离体猪和大鼠左房心肌细胞I-1c基因转移增加钙瞬变幅度。
  • 未发现不良电重构、致心律失常性、细胞免疫反应激活或靶器官损伤的证据。

临床怎么用

  • 该基因治疗策略在非缺血性心衰大动物模型中显示出改善收缩功能和安全性,但尚未进入临床实践。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Increased protein phosphatase-1 in heart failure (HF) induces molecular changes deleterious to the cardiac cell. Inhibiting protein phosphatase-1 through the overexpression of a constitutively active inhibitor-1 (I-1c) has been shown to reverse cardiac dysfunction in a model of ischemic HF. OBJECTIVES: This study sought to determine the therapeutic efficacy of a re-engineered adenoassociated viral vector carrying I-1c (BNP116.I-1c) in a preclinical model of nonischemic HF, and to assess thoroughly the safety of BNP116.I-1c gene therapy. METHODS: Volume-overload HF was created in Yorkshire swine by inducing severe mitral regurgitation. One month after mitral regurgitation induction, pigs were randomized to intracoronary delivery of either BNP116.I-1c (n = 6) or saline (n = 7). Therapeutic efficacy and safety were evaluated 2 months after gene delivery. Additionally, 24 naive pigs received different doses of BNP116.I-1c for safety evaluation. RESULTS: At 1 month after mitral regurgitation induction, pigs developed HF as evidenced by increased left ventricular end-diastolic pressure and left ventricular volume indexes. Treatment with BNP116.I-1c resulted in improved left ventricular ejection fraction (-5.9 ± 4.2% vs. 5.5 ± 4.0%; p < 0.001) and adjusted dP/dt maximum (-3.39 ± 2.44 s-1 vs. 1.30 ± 2.39 s-1; p = 0.007). Moreover, BNP116.I-1c-treated pigs also exhibited a significant increase in left atrial ejection fraction at 2 months after gene delivery (-4.3 ± 3.1% vs. 7.5 ± 3.1%; p = 0.02). In vitro I-1c gene transfer in isolated left atrial myocytes from both pigs and rats increased calcium transient amplitude, consistent with its positive impact on left atrial contraction. We found no evidence of adverse electrical remodeling, arrhythmogenicity, activation of a cellular immune response, or off-target organ damage by BNP116.I-1c gene therapy in pigs. CONCLUSIONS: Intracoronary delivery of BNP116.I-1c was safe and improved contractility of the left ventricle and atrium in a large animal model of nonischemic HF.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Watanabe S, Ishikawa K, Fish K, et al. Protein Phosphatase Inhibitor-1 Gene Therapy in a Swine Model of Nonischemic Heart Failure. J Am Coll Cardiol. 2017. PMID: 28958332. doi:10.1016/j.jacc.2017.08.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。